High Atlastin 2-2 (ATL2-2) Expression Associates with Worse Prognosis in Estrogen-Receptor-Positive Breast Cancer
Genes · 2023
DOI: 10.3390/genes14081559 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2023. Verfasst von Inga Reynisdottir und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cell Biology Unit, Department of Pathology, Landspitali-The National University Hospital of Iceland, 101 Reykjavik, Iceland. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Scientific Fund of Landspitali—The National University Hospital in Iceland.
Abstract (Originalsprache)
The disruption of endoplasmic reticulum (ER) homeostasis occurs in many human diseases. Atlastins (ATLs) maintain the branched network of the ER. The dysregulation of ATL2, located at ER network junctions, has been associated with cancer. ATL2 is necessary for lipid droplet formation in murine breast tissue. Thus, we analyzed whether ATL2 has a role in human breast cancer (BC) pathology. The expression of ATL2 variant ATL2-2 was analyzed in breast tumors from the BC cohorts of the TCGA, METABRIC, and two independent Icelandic cohorts, Cohort 1 and 2; its association with clinical, pathological, survival, and cellular pathways was explored. ATL2-2 mRNA and protein expression were higher in breast tumors than in normal tissue. ATL2-2 mRNA associated with tumor characteristics that indicate a worse prognosis. In METABRIC, high ATL2-2 mRNA levels were associated with shorter BC-specific survival (BCSS) in patients with estrogen-receptor-positive luminal breast tumors, which remained significant after correction for grade and tumor size (HR 1.334, CI 1.063–1.673). Tumors with high ATL2 mRNA showed an upregulation of hallmark pathways MYC targets v1, E2F targets, and G2M checkpoint genes. Taken together, the results suggest that high levels of ATL2-2 may support BC progression through key cancer driver pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cell Biology Unit, Department of Pathology, Landspitali-The National University Hospital of Iceland, 101 Reykjavik, Iceland.
- BMC (Biomedical Center), Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland.
- Molecular Pathology Unit, Department of Pathology, Landspitali-The National University Hospital of Iceland, 101 Reykjavik, Iceland.
- Department of Pathology, Landspitali-The National University Hospital of Iceland, 101 Reykjavik, Iceland.
- Department of Oncology, Landspitali-The National University Hospital of Iceland, 101 Reykjavik, Iceland.
- Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland.
ORCID-Profile: Inga Reynisdottir, Gunnhildur A Traustadottir
Förderung
- The Scientific Fund of Landspitali—The National University Hospital in Iceland
Zitieren
APA
Reynisdottir, I., Arason, A., Freysteinsdottir, E. S., Kristjansdottir, S. B., Hilmarsdottir, B., Traustadottir, G. A., Johannsson, O. T., Agnarsson, B. A., & Barkardottir, R. B. (2023). High Atlastin 2-2 (ATL2-2) Expression Associates with Worse Prognosis in Estrogen-Receptor-Positive Breast Cancer. Genes. https://doi.org/10.3390/genes14081559
Vancouver
Reynisdottir I, Arason A, Freysteinsdottir ES, Kristjansdottir SB, Hilmarsdottir B, Traustadottir GA, et al. High Atlastin 2-2 (ATL2-2) Expression Associates with Worse Prognosis in Estrogen-Receptor-Positive Breast Cancer. Genes. 2023. doi:10.3390/genes14081559
BibTeX
@article{Reynisdottir2023,
author = {Reynisdottir, Inga and Arason, Adalgeir and Freysteinsdottir, Edda S and Kristjansdottir, Sigrun B and Hilmarsdottir, Bylgja and Traustadottir, Gunnhildur A and Johannsson, Oskar T and Agnarsson, Bjarni A and Barkardottir, Rosa B},
title = {High Atlastin 2-2 (ATL2-2) Expression Associates with Worse Prognosis in Estrogen-Receptor-Positive Breast Cancer},
journal = {Genes},
year = {2023},
doi = {10.3390/genes14081559}
}
EUVIMED